Cannabinoids In Attention-deficit/hyperactivity Disorder: A Randomised-controlled Trial
Notes for this study:
|Number of Subjects
||18-29, 30-44, 45-64
In a 6-week randomized, double-blind, placebo-controlled trial, 30 adults (18-55) with ADHD took Sativex Oromucosal Spray, which contains 2.7 mg delta-9-tetrahydrocannabinol (Δ9-THC) and 2.5 mg cannabidiol per 100 microlitres or placebo. There was a titration period where, for two weeks, the dose was increased until the optimal dose with the fewest adverse effects was found and continued for the rest of the study.
Funding issues for this study:
The primary outcome was the performance on QbTest, and there wasn't a statistically significant difference in the intention to treat analysis. However, there was a trend towards better performance in the intervention groups. There weren't statistically significant differences for the Sustained Attention to Response Task (SART).
There was significantly less hyperactivity/impulsivity, nonsignificantly less inattention, and less emotional ability in the intervention group, but the difference wasn't statistically significant.
"At the time this work was undertaken, Ruth Cooper was a Ph.D.
student at King’s College London (KCL) funded by a research grant
to Philip Asherson from Vifor Pharma. Philip Asherson received funds
for consultancy or sponsored talks on behalf of KCL for Shire, Lilly,
Novartis, Janssen and PCM Scientific. He received research or
education funds on behalf of KCL from Shire, Lilly, Novartis,
Janssen, Vifor Pharma and QB Tech. The Sativex medication was
provided free of charge to Philip Asherson from GW Pharma."